Comprehensive microRNA analysis in bleomycin-induced pulmonary fibrosis identifies multiple sites of molecular regulation.
暂无分享,去创建一个
P. Noble | J. Liang | D. Jiang | T. Xie | R. Guo | Ningshan Liu | Jiurong Liang | N. Liu
[1] Xiao-ming Meng,et al. miR-192 mediates TGF-beta/Smad3-driven renal fibrosis. , 2010, Journal of the American Society of Nephrology : JASN.
[2] Oliver Eickelberg,et al. Inhibition and role of let-7d in idiopathic pulmonary fibrosis. , 2010, American journal of respiratory and critical care medicine.
[3] R. Homer,et al. Inhibition of pulmonary fibrosis in mice by CXCL10 requires glycosaminoglycan binding and syndecan-4. , 2010, The Journal of clinical investigation.
[4] Oliver Distler,et al. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. , 2010, Arthritis and rheumatism.
[5] N. Kaminski,et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis , 2010, The Journal of experimental medicine.
[6] R. Khanin,et al. Dynamic Changes in Lung MicroRNA Profiles During the Development of Pulmonary Hypertension due to Chronic Hypoxia and Monocrotaline , 2010, Arteriosclerosis, thrombosis, and vascular biology.
[7] Robert H. Jenkins,et al. Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy. , 2010, Journal of the American Society of Nephrology : JASN.
[8] J. Rosenbloom,et al. Narrative Review: Fibrotic Diseases: Cellular and Molecular Mechanisms and Novel Therapies , 2010, Annals of Internal Medicine.
[9] Kazuhiro Yoshida,et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. , 2010, The Lancet. Oncology.
[10] P. Meda,et al. Involvement of MicroRNAs in the Cytotoxic Effects Exerted by Proinflammatory Cytokines on Pancreatic β-Cells , 2010, Diabetes.
[11] R. Stallings,et al. miR-126 Is Downregulated in Cystic Fibrosis Airway Epithelial Cells and Regulates TOM1 Expression , 2010, The Journal of Immunology.
[12] J. Araya,et al. Fibrogenic reactions in lung disease. , 2010, Annual review of pathology.
[13] Xinxia Peng,et al. MicroRNA Expression and Virulence in Pandemic Influenza Virus-Infected Mice , 2010, Journal of Virology.
[14] Susumu Goto,et al. KEGG for representation and analysis of molecular networks involving diseases and drugs , 2009, Nucleic Acids Res..
[15] Zsolt Czimmerer,et al. DIFFERENTIALLY EXPRESSED MicroRNAs IN SMALL CELL LUNG CANCER , 2009, Experimental lung research.
[16] P. Barbry,et al. Identification of Keratinocyte Growth Factor as a Target of microRNA-155 in Lung Fibroblasts: Implication in Epithelial-Mesenchymal Interactions , 2009, PloS one.
[17] Chiwai Wong,et al. Downregulations of B‐cell lymphoma 2 and myeloid cell leukemia sequence 1 by microRNA 153 induce apoptosis in a glioblastoma cell line DBTRG‐05MG , 2009, International journal of cancer.
[18] G. Jenkins,et al. Role of integrin-mediated TGFbeta activation in the pathogenesis of pulmonary fibrosis. , 2009, Biochemical Society transactions.
[19] I. Rigoutsos. New tricks for animal microRNAS: targeting of amino acid coding regions at conserved and nonconserved sites. , 2009, Cancer research.
[20] M. Wolzt,et al. In vivo profile of the human leukocyte microRNA response to endotoxemia. , 2009, Biochemical and biophysical research communications.
[21] R. Chambers. Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention? , 2008, British journal of pharmacology.
[22] C. Marsh,et al. The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis. , 2008, Antioxidants & redox signaling.
[23] P. Noble,et al. Hyaluronan in tissue injury and repair. , 2007, Annual review of cell and developmental biology.
[24] A. Greenberg,et al. The role of TGF-beta in pulmonary fibrosis. , 2007, Ciba Foundation symposium.
[25] P. Sime,et al. TGF-β, Smad3 and the process of progressive fibrosis , 2007 .
[26] Jeffrey T. Chang,et al. GATHER: a systems approach to interpreting genomic signatures , 2006, Bioinform..
[27] J. Horowitz,et al. Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. , 2006, Proceedings of the American Thoracic Society.
[28] A. Schnapp,et al. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. , 2006, American journal of respiratory and critical care medicine.
[29] Johny Verschakelen,et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. , 2005, The New England journal of medicine.
[30] G. Prestwich,et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan , 2005, Nature Medicine.
[31] T. Oury,et al. Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. , 2005, American journal of respiratory and critical care medicine.
[32] J. Köhl,et al. Opposing Regulatory Roles of Complement Factor 5 in the Development of Bleomycin-Induced Pulmonary Fibrosis1 , 2005, The Journal of Immunology.
[33] R. Homer,et al. Back to the future: historical perspective on the pathogenesis of idiopathic pulmonary fibrosis. , 2005, American journal of respiratory cell and molecular biology.
[34] R. Homer,et al. Idiopathic pulmonary fibrosis: new insights into pathogenesis. , 2004, Clinics in chest medicine.
[35] Anton J. Enright,et al. Human MicroRNA Targets , 2004, PLoS biology.
[36] Lin He,et al. MicroRNAs: small RNAs with a big role in gene regulation , 2004, Nature Reviews Genetics.
[37] R. Homer,et al. Regulation of pulmonary fibrosis by chemokine receptor CXCR3. , 2004, The Journal of clinical investigation.
[38] M. Selman,et al. The epithelial/fibroblastic pathway in the pathogenesis of idiopathic pulmonary fibrosis. , 2003, American journal of respiratory cell and molecular biology.
[39] Rakesh K. Kumar. Idiopathic pulmonary fibrosis: an epithelial/fibroblastic cross-talk disorder , 2002, Respiratory Research.
[40] V. Ambros. microRNAs Tiny Regulators with Great Potential , 2001, Cell.
[41] V. Ambros,et al. An Extensive Class of Small RNAs in Caenorhabditis elegans , 2001, Science.
[42] L. Lim,et al. An Abundant Class of Tiny RNAs with Probable Regulatory Roles in Caenorhabditis elegans , 2001, Science.
[43] B. Uhal,et al. Abrogation of bleomycin-induced epithelial apoptosis and lung fibrosis by captopril or by a caspase inhibitor. , 2000, American journal of physiology. Lung cellular and molecular physiology.
[44] S. Nagata,et al. Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. , 1999, The Journal of clinical investigation.
[45] A. Boobis,et al. Pulmonary fibrosis correlates with duration of tissue neutrophil activation. , 1998, American journal of respiratory and critical care medicine.
[46] M. Kanehisa. A database for post-genome analysis. , 1997, Trends in genetics : TIG.
[47] T. Colby,et al. Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[48] R. Hällgren,et al. Accumulation of hyaluronic acid in the alveolar interstitial tissue in bleomycin-induced alveolitis. , 1989, The American review of respiratory disease.
[49] C. Haslett,et al. The intensity of chronic lung inflammation and fibrosis after bleomycin is directly related to the severity of acute injury. , 1988, The American review of respiratory disease.
[50] F. Orr,et al. Effects of injury and repair of the pulmonary endothelium on lung metastasis after bleomycin , 1986, The Journal of pathology.
[51] I. Adamson,et al. Bleomycin-induced injury and metaplasia of alveolar type 2 cells. Relationship of cellular responses to drug presence in the lung. , 1979, The American journal of pathology.
[52] Thomas D. Schmittgen,et al. Integrating the MicroRNome into the study of lung disease. , 2009, American journal of respiratory and critical care medicine.
[53] D. Warburton,et al. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? , 2008, The international journal of biochemistry & cell biology.
[54] P. Sime,et al. TGF-beta, Smad3 and the process of progressive fibrosis. , 2007, Biochemical Society transactions.
[55] Naomi Altman,et al. Replication, Variation and Normalisation in Microarray Experiments , 2005, Applied bioinformatics.
[56] V. Poletti,et al. Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. , 2003, The American journal of pathology.
[57] V. Poletti,et al. Aberrant Wnt/ (cid:1) -Catenin Pathway Activation in Idiopathic Pulmonary Fibrosis , 2003 .
[58] David A. Lynch,et al. Idiopathic pulmonary fibrosis: Diagnosis and treatment: International Consensus Statement , 2000 .
[59] American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). , 2000, American journal of respiratory and critical care medicine.
[60] F. Marincola,et al. Human Cancer Biology Microrna Expression Differentiates Histology and Predicts Survival of Lung Cancer Clinical Cancer Research Authors' Affiliations: Divisions of 1 Cancer Epidemiology and Genetics and 2 Cancer Treatment and Diagnosis , 2022 .